COLTHERES
Modelling and predicting sensitivity to targeted therapies in colorectal cancers
| Coordinatore | UNIVERSITA DEGLI STUDI DI TORINO
Organization address
address: Via Giuseppe Verdi 8 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Sito del progetto | http://www.coltheres.eu/ |
| Totale costo | 8˙200˙254 € |
| EC contributo | 5˙999˙300 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-01-01 - 2014-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITA DEGLI STUDI DI TORINO
Organization address
address: Via Giuseppe Verdi 8 contact info |
IT (TORINO) | coordinator | 1˙507˙200.00 |
| 2 |
Horizon Discovery Limited
Organization address
address: CAMBRIDGE RESEARCH PARK contact info |
UK (Cambridge) | participant | 920˙520.00 |
| 3 |
STICHTING HET NEDERLANDS KANKER INSTITUUT
Organization address
address: PLESMANLAAN 121 contact info |
NL (AMSTERDAM) | participant | 641˙200.00 |
| 4 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 498˙400.00 |
| 5 |
Agendia BV
Organization address
address: Science Park 406 contact info |
NL (Amsterdam) | participant | 490˙500.00 |
| 6 |
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203 contact info |
ES (L'HOSPITALET DE LLOBREGAT) | participant | 419˙200.00 |
| 7 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: Brownlow Hill, Foundation Building 765 contact info |
UK (LIVERPOOL) | participant | 348˙700.00 |
| 8 |
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON
Organization address
city: Barcelona contact info |
ES (Barcelona) | participant | 333˙900.00 |
| 9 |
SWISS INSTITUTE OF BIOINFORMATICS
Organization address
address: Rue Michel Servet 1 contact info |
CH (GENEVE) | participant | 320˙880.00 |
| 10 |
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA
Organization address
address: PIAZZA OSPEDALE MAGGIORE 3 contact info |
IT (MILANO) | participant | 314˙800.00 |
| 11 |
ARTTIC IN BRUSSELS SPRL
Organization address
address: RUE DE LIVOURNE 7 bte 4 contact info |
BE (BRUXELLES) | participant | 204˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk and patient-response stratification criteria, which can then be used to rationally develop companion diagnostic assays and more stream-lined clinical trials. COLTHERES will address these key issues by: 1) Molecularly profiling colon cancer patient samples using multiple ‘omics based technologies for co-segregating lesions that could impart resistance to existing and emerging targeted therapies 2) The building and screening of predictive in vitro models based on this data, to enable the rapid and empirical determination of drug resistance biomarkers 3) The use of these models and of the clinical studies to prospectively screen for genes mediating resistance and sensitivity to targeted therapies in CRCs 4) The building of new algorithms to significantly accelerate the design of rational therapies, by integrating more predictive models, assays and biomarkers into all phases of drug discovery; including novel phase-0 (xenopatients) studies 5) The design of innovative and focused biomarker driven phase II trials based on knowledge gathered within the project
COLTHERES has assembled a unique consortium, from both academia and industrial SMEs, of world- experts in the areas of; • clinical design of innovative biomarker trials and improved therapeutic strategies • ‘omics technologies including genomic, transcriptomic, epigenomic and proteomic profiling • Functional genomic and disease model-generation • Bio-informatics and data analysis, to handle and interrogate the complexity of the data generated through the various approaches'
Introduzione (Teaser)
A main limitation of targeted therapies in colorectal cancer is the emergence of secondary resistance. European scientists are prospectively screening for genes that mediate such acquired resistance, aiming to identify specific drug resistance biomarkers.